<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple system atrophy: Prognosis and treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple system atrophy: Prognosis and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple system atrophy: Prognosis and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stewart A Factor, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christine Doss Esper, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard I Hurtig, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple system atrophy (MSA) is a unifying term that brings together a group of rare, fatal neurodegenerative syndromes that used to be referred to as olivopontocerebellar atrophy, striatonigral degeneration, and Shy-Drager syndrome. They have similar pathology and are characterized by various degrees of autonomic dysfunction, cerebellar abnormalities, parkinsonism, and corticospinal degeneration.</p><p>This topic will review the prognosis and management of MSA. Other clinical aspects of MSA are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">"Multiple system atrophy: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Disease progression in MSA usually occurs over 1 to 18 years, and is often faster than that of idiopathic Parkinson disease [<a href="#rid1">1</a>].</p><p>In mainly retrospective studies, the median times from disease onset to disability milestones in MSA were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Development of autonomic dysfunction, 2.5 years [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Need for walking aid, 3 years [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Wheelchair confinement, 3.5 to 5 years [<a href="#rid2">2,3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Bedridden state, 5 to 8 years [<a href="#rid2">2,3</a>]</p><p></p><p>The median time from MSA onset to death is 6 to 10 years [<a href="#rid2">2-9</a>]. However, survival is quite variable, and some patients with MSA live for 15 years or more after symptom onset [<a href="#rid7">7,10,11</a>]. In particular, patients with a disease onset before age 40 years, also known as young-onset MSA, may have a longer survival than typically reported for MSA more generally [<a href="#rid12">12</a>].</p><p>In various studies, risk factors for <strong>shorter</strong> survival include the following [<a href="#rid2">2,3,5,7,8,11,13-18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A diagnosis of the parkinsonian variant of MSA (MSA-P)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incomplete bladder emptying</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older age at disease onset</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early or severe autonomic failure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early stridor onset (eg, within three years from motor or autonomic symptom onset)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female sex</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A short time from disease onset to the first clinical milestone of disability (frequent falling, cognitive disability, unintelligible speech, severe dysphagia, wheelchair dependence, urinary catheter use)</p><p></p><p>Neurofilament light chain protein has been explored as a potential biomarker that correlates with clinical disease severity, progression, and prognosis [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>No effective disease-modifying or neuroprotective treatment is available for MSA [<a href="#rid20">20-22</a>]. Management, limited as it is, is primarily symptomatic.</p><p>The main clinical features of MSA are parkinsonism, autonomic failure, cerebellar ataxia, and pyramidal signs in varying combinations. Additional manifestations can include sleep disorders, breathing disorders, and depression. (See  <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">"Multiple system atrophy: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>The motor symptoms in MSA are generally resistant to pharmacologic treatment. However, the autonomic symptoms may respond to pharmacotherapy. Physical, occupational, and speech therapy are helpful for the supportive care of patients with MSA.</p><p class="headingAnchor" id="H612795568"><span class="h2">Levodopa and dopaminergic therapy</span><span class="headingEndMark"> — </span>The main role of levodopa in patients with suspected MSA is diagnostic; a poor or unsustained response to levodopa therapy is generally observed in patients with MSA and can help to distinguish the parkinsonian variant of MSA (MSA-P) from idiopathic Parkinson disease. However, some patients with clinically probable MSA do better on levodopa treatment than off it, and some also develop motor fluctuations and dyskinesia. (See  <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">"Multiple system atrophy: Clinical features and diagnosis", section on 'Levodopa response assessment'</a>.)</p><p>Therefore, we suggest a trial of levodopa for patients with suspected MSA. Levodopa is given with a peripheral decarboxylase inhibitor (eg, levodopa-carbidopa) in escalating doses up to 1000 mg of levodopa daily as necessary and tolerated over a three-month period. The total daily dose must be increased to 900 or 1000 mg before a trial of levodopa can be declared a failure. Clinical improvement is characterized as a 30 percent decrease in the Unified MSA Rating Scale (UMSARS) [<a href="#rid10">10</a>]. For patients with advanced disease who have demonstrated oral levodopa responsiveness, levodopa-carbidopa intestinal gel (LCIG) is a device-assisted option that may improve global function scores and allow for discontinuation of oral antiparkinsonian drugs in some patients [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">"Device-assisted and lesioning procedures for Parkinson disease", section on 'Continuous levodopa-carbidopa intestinal gel infusion'</a>.)</p><p><a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">Amantadine</a> has been used in doses up to 300 mg per day to treat MSA, but it is no more effective than levodopa [<a href="#rid24">24</a>].</p><p>The role for dopamine agonists is limited. They rarely lead to motor benefit and frequently exacerbate orthostatic hypotension, gastrointestinal symptoms, and sleep disorders that are prevalent in MSA. Patients who do not respond to levodopa are unlikely to respond to dopamine agonists, so their use should be avoided.</p><p class="headingAnchor" id="H4"><span class="h2">Motor symptoms</span><span class="headingEndMark"> — </span>There are no effective medications for the ataxia and gait abnormalities that predominate in the cerebellar subtype of MSA [<a href="#rid10">10</a>]. Furthermore, the parkinsonian manifestations of bradykinesia and rigidity in MSA are often but not always resistant to treatment. Approximately 30 to 50 percent of MSA-P patients have some response.</p><p class="bulletIndent1"><span class="glyph">●</span>Physical therapy is important for fall prevention, reduction in contractures, and maintenance of mobility while possible. Therapists are also helpful in determining requirements for and facilitating walker and wheelchair use when a patient becomes nonambulatory. Randomized controlled trials support occupational therapy in mild to moderate MSA [<a href="#rid25">25</a>], and it may promote longer independence in performing activities of daily living. Additionally, in-home visits for safety evaluation and driving evaluations are beneficial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Botulinum toxin injection is often useful in alleviating symptoms of focal dystonias that occur in MSA, such as cervical dystonia and blepharospasm. Caution is advised when injecting an MSA patient for cervical dystonia, given the risk of potentially exacerbating underlying dysphagia often associated with the disease [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults", section on 'Focal dystonia'</a>.)</p><p></p><p>For patients with anterocollis, it is important to differentiate dystonia from myopathy as the cause. This should be done before using botulinum toxin, which may worsen symptoms when myopathy is the cause. Electromyography usually clarifies the picture, although biopsy may be necessary when the diagnosis is uncertain.</p><p>Speech therapy referral early in the course of disease allows objective determination of the progression of dysphagia. The need for percutaneous gastrostomy tube placement should be assessed by videofluoroscopic swallow evaluation and <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> swallow studies.</p><p class="headingAnchor" id="H6"><span class="h2">Orthostatic hypotension</span><span class="headingEndMark"> — </span>Symptomatic orthostatic hypotension due to neurodegenerative dysautonomia affects approximately three-quarters of patients with MSA. Recognition and treatment are key components of supportive care in an effort to prevent falls and other complications and to improve quality of life.</p><p>Treatment in patients with MSA is the same as for other causes of neurogenic orthostatic hypotension and includes nonpharmacologic  (<a class="graphic graphic_table graphicRef130806" href="/z/d/graphic/130806.html" rel="external">table 1</a>) and pharmacologic measures  (<a class="graphic graphic_table graphicRef130807" href="/z/d/graphic/130807.html" rel="external">table 2</a>) as well as avoidance of aggravating medications when possible  (<a class="graphic graphic_table graphicRef130809" href="/z/d/graphic/130809.html" rel="external">table 3</a>). An approach to medication selection is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef130808" href="/z/d/graphic/130808.html" rel="external">algorithm 1</a>) and reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">"Treatment of orthostatic and postprandial hypotension"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Postprandial hypotension</span><span class="headingEndMark"> — </span>Optimal therapy of symptomatic postprandial hypotension has not been defined. Modification of meals may be helpful in selected patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid large meals</p><p class="bulletIndent1"><span class="glyph">●</span>Eat low-carbohydrate meals</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid salt restriction</p><p class="bulletIndent1"><span class="glyph">●</span>Drink water with meals</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid standing up suddenly or standing still after meals</p><p class="bulletIndent1"><span class="glyph">●</span>Walk between meals; if walking is not tolerated, lie semirecumbent for 90 minutes after meals</p><p></p><p>Several medications have been shown to improve blood pressure in postprandial hypotension and may be used in refractory cases, including somatostatin analogues. Supporting evidence and administration are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">"Treatment of orthostatic and postprandial hypotension", section on 'Postprandial hypotension'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Urogenital symptoms</span><span class="headingEndMark"> — </span>Overactive bladder symptoms due to detrusor overactivity (also referred to as detrusor hyperreflexia) are an early and common manifestation of autonomic dysfunction in patients with MSA [<a href="#rid27">27,28</a>]. Symptoms include urinary urgency, urinary frequency, nocturia, and urge incontinence. Patients with MSA are also at risk for urinary retention, and ultrasound to measure postvoid residual volumes should generally be performed before starting symptomatic medications and in patients with new or worsening urinary symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overactive bladder</strong> – For overactive bladder, the initial approach is similar to that in the general population, including education about lifestyle modifications (eg, reducing consumption of mild diuretics like <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> and alcohol, avoiding fluids before bedtime), prompted/timed bladder emptying, and behavioral therapies such as pelvic floor muscle training. (See  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment", section on 'Initial approach to treatment'</a> and  <a class="medical medical_review" href="/z/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Patient evaluation'</a>.)</p><p></p><p class="bulletIndent1">Adjunctive medications for overactive bladder should be offered in patients with residual bothersome symptoms [<a href="#rid27">27</a>]. First-line therapies include beta-3 adrenergic agonists (eg, <a class="drug drug_general" data-topicid="85675" href="/z/d/drug information/85675.html" rel="external">mirabegron</a>, <a class="drug drug_general" data-topicid="130397" href="/z/d/drug information/130397.html" rel="external">vibegron</a>) and antimuscarinic drugs. All medications should be started at low doses and titrated slowly to reduce the risk of side effects.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="85675" href="/z/d/drug information/85675.html" rel="external">Mirabegron</a> may have the most favorable adverse event profile in patients with MSA and does not cause cognitive side effects. Emerging data support its efficacy and tolerability in patients with Parkinson disease [<a href="#rid29">29-31</a>]. The starting dose is one 25 mg extended-release tablet daily. Mirabegron can cause hypertension and should not be used in patients with severe or uncontrolled hypertension. Further details on administration and monitoring are provided separately. (See  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment", section on 'Beta-3 adrenergic agonists'</a>.)</p><p></p><p class="bulletIndent1">Among the antimuscarinic agents, those with low central nervous system penetration (eg, <a class="drug drug_general" data-topicid="9266" href="/z/d/drug information/9266.html" rel="external">darifenacin</a>, <a class="drug drug_general" data-topicid="10313" href="/z/d/drug information/10313.html" rel="external">solifenacin</a>, <a class="drug drug_general" data-topicid="10320" href="/z/d/drug information/10320.html" rel="external">trospium</a>) are preferred due to lower risk of neurocognitive side effects. Solifenacin has been studied specifically in patients with Parkinson disease [<a href="#rid32">32</a>]. Older drugs like <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a> and <a class="drug drug_general" data-topicid="10292" href="/z/d/drug information/10292.html" rel="external">tolterodine</a> should be avoided if possible in patients with MSA due to higher risk of confusion and worsening constipation.</p><p></p><p class="bulletIndent1">Alpha-adrenergic blockers (eg, <a class="drug drug_general" data-topicid="9654" href="/z/d/drug information/9654.html" rel="external">tamsulosin</a>, <a class="drug drug_general" data-topicid="9520" href="/z/d/drug information/9520.html" rel="external">silodosin</a>) can exacerbate orthostatic hypotension and should be used very cautiously, if at all, for urinary symptoms [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">Patients with refractory symptoms may be referred to urology for consideration of options such as implantable stimulators (sacral nerve and tibial nerve) and intramural botulinum toxin injections. (See  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment", section on 'Patients with continued symptoms'</a> and  <a class="medical medical_review" href="/z/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Refractory OAB'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary retention</strong> – For bladder atony, intermittent self-catheterization should be used for retention or residual volume &gt;100 mL. As the severity of bladder dysfunction progresses, a permanent transcutaneous suprapubic catheter may be required [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/8090.html" rel="external">"Placement and management of urinary bladder catheters in adults", section on 'Clean intermittent catheterization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erectile dysfunction</strong> – The treatment of erectile dysfunction is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Depression</span><span class="headingEndMark"> — </span>Depression is a common problem in patients with MSA, often requiring psychiatric treatment with counseling for the patient and family, and in some cases antidepressant pharmacotherapy. (See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.)</p><p class="headingAnchor" id="H3819208606"><span class="h2">Stridor</span><span class="headingEndMark"> — </span>Laryngeal stridor in patients with MSA typically occurs during sleep, although daytime symptoms can emerge in advanced cases. Sleep dysfunction is a major cause of death in MSA [<a href="#rid35">35,36</a>] and warrants further evaluation.</p><p>We refer patients with symptomatic stridor to otolaryngology and sleep medicine for overnight polysomnography. For most patients, initial symptomatic therapy consists of nocturnal continuous positive airway pressure (CPAP). Adaptive servo-ventilation (ASV) is sometimes used instead of CPAP when there is concurrent central sleep apnea [<a href="#rid37">37</a>]. Based on small short-term retrospective studies, CPAP often eliminates stridor [<a href="#rid38">38-41</a>]. Long-term symptomatic effects are not well studied. A 2019 systematic review and consensus statement concluded that the impact of CPAP on overall survival is uncertain [<a href="#rid42">42</a>].</p><p>Patients with persistent and severe stridor that does not respond to CPAP or ASV or in whom these are not feasible may require tracheostomy for symptomatic control. Tracheostomy for stridor typically involves placement of a fenestrated cannula, which is maintained in a closed position during the day to allow for phonation and opened at night to bypass airway obstruction at the larynx and relieve distressing stridor [<a href="#rid42">42</a>]. Whether tracheostomy prevents sudden death in sleep due to airway obstruction is not known, but observational studies have suggested that tracheostomy may prolong survival in patients with MSA [<a href="#rid2">2,15,43,44</a>]. In one retrospective study of 75 patients with MSA and stridor, 22 patients were treated with tracheostomy, 29 with CPAP, and 24 with no treatment. Tracheostomy was associated with longer survival compared with CPAP or no treatment (incidence rate of death 12 versus 21 versus 23 per 100 person-years, respectively). Tracheostomy remained an independent predictor of longer survival after adjustment for confounders. There have been reports of worsening central sleep apnea after tracheostomy in MSA [<a href="#rid45">45</a>], and patients who undergo tracheostomy should be followed by a pulmonary and/or sleep specialist.</p><p class="headingAnchor" id="H10"><span class="h2">Rapid eye movement sleep behavior disorder</span><span class="headingEndMark"> — </span>Patients with rapid eye movement sleep behavior disorder and their bed partners should be counseled on ways to alter the sleeping environment to prevent injury  (<a class="graphic graphic_algorithm graphicRef134977" href="/z/d/graphic/134977.html" rel="external">algorithm 2</a>). Effective pharmacotherapy options include melatonin and <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>  (<a class="graphic graphic_table graphicRef96339" href="/z/d/graphic/96339.html" rel="external">table 4</a>). Treatment is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">"Rapid eye movement sleep behavior disorder", section on 'Management'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Support groups</span><span class="headingEndMark"> — </span>Local, regional, and national associations can play an integral role to benefit lives of patients, family members, and caregivers. These groups include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.apdaparkinson.org%2F&amp;token=j%2BtF41plvYHq0KcVLVNCguOqGNyvXuO5ZuQ2EjGbPl0fIE6yzR9tEmBJEL01O7rP&amp;TOPIC_ID=4891" target="_blank">The American Parkinson Disease Association</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.parkinson.org%2F&amp;token=kgWnuLuwd5ywHVQww%2BY9er08fegQ6vhK4mcBCKVUx77U9U9rg7kJqPNEqR8W3N9e&amp;TOPIC_ID=4891" target="_blank">The Parkinson's Foundation</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.multiplesystematrophy.org%2F&amp;token=P5Od9O29Gx2epFPupdzNG4PNuMrz3I1d%2FvCqPoqpXw6400HEGgXQq0PMxOJoQIC%2F&amp;TOPIC_ID=4891" target="_blank">The Multiple System Atrophy Coalition</a></p><p></p><p class="headingAnchor" id="H615066360"><span class="h1">INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>There is currently no effective disease-modifying or neuroprotective treatment for MSA. Several early therapeutic attempts with general neuroprotective drugs such as <a class="drug drug_general" data-topicid="10338" href="/z/d/drug information/10338.html" rel="external">rasagiline</a>, coenzyme Q10, <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">riluzole</a>, and others failed in phase III trials [<a href="#rid21">21</a>]. Strategies currently under investigation include reducing alpha-synuclein aggregation and pathology as well as modulating neuroinflammation [<a href="#rid46">46</a>].</p><p>Disease-specific strains of alpha-synuclein exist in MSA compared with Parkinson disease and dementia with Lewy bodies, indicating the possible need for individualized approaches of the therapies targeting alpha-synuclein. A majority of the developed therapeutic approaches have focused on enhancing alpha-synuclein degradation and preventing or disrupting its aggregation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced alpha-synuclein degradation</strong> – Initial studies were based on inducing alpha-synuclein degradation by stimulating macro-autophagy using agents such as rapamycin, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, and the c-Abl inhibitor <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a>; all of these were found to be ineffective [<a href="#rid21">21,47</a>]. Other approaches include increasing the extracellular alpha-synuclein clearance to promote its degradation by microglial cells such as toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPLA).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced alpha-synuclein aggregation</strong> – Small molecules such as Anle138b have shown promise in preventing alpha-synuclein accumulation or disrupting the formation of toxic oligomeric species. The small molecule ATH434 is a moderate iron chelator shown to reduce alpha-synuclein accumulation by redistributing labile iron in the brain.</p><p></p><p class="bulletIndent1">Another approach is the use of anti-alpha-synuclein immunotherapies (both passive and active) with specific binding of the antigen alpha-synuclein and its respective antibody, followed by clearance of the complexes. Lu AF82422 is one anti-alpha-synuclein human immunoglobulin G1 monoclonal antibody being examined. Such vaccination studies are in early-phase trials. Active immunotherapies develop antibodies against an epitope similar to alpha-synuclein [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent1">Antisense oligonucleotides are an alternative therapeutic approach to suppress the production of alpha-synuclein and therefore reduce its intracellular toxic accumulation. Infusing autologous mesenchymal stem cells may theoretically have a neuroprotective effect [<a href="#rid50">50-53</a>]. These treatments are currently in preclinical or early-phase clinical development.</p><p></p><p>Verdiperstat, an oral, brain-penetrant, irreversible inhibitor of myeloperoxidase (MPO; which is an enzyme that impels oxidative and neuroinflammatory processes that underlie neurodegeneration), has received orphan drug designation from the US Food and Drug Administration (FDA). In phase I clinical trials, after 12 weeks of treatment, placebo-treated patients worsened by 4.6 points on the Unified MSA Rating Scale (UMSARS), while verdiperstat-treated patients worsened by 3.7 points at the 300 mg twice-daily dose and by 2.6 points at the 600 mg twice-daily dose [<a href="#rid54">54</a>]. A phase III trial was unfortunately reported to be negative. The details of the study have not been published.</p><p>There is a growing list of agents in the preclinical treatment pipeline [<a href="#rid21">21,55</a>].</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardinal features</strong> – Multiple system atrophy (MSA) is a rare neurodegenerative movement disorder characterized by parkinsonism, autonomic failure, cerebellar ataxia, and pyramidal signs in varying combinations. (See  <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">"Multiple system atrophy: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – There is no effective disease-modifying or neuroprotective treatment for MSA. Management focuses on symptom control and quality of life.</p><p></p><p class="bulletIndent1">Disease progression in MSA is often faster than in idiopathic Parkinson disease, as illustrated by median times from MSA symptom onset to autonomic dysfunction (2.5 years), wheelchair confinement (3.5 to 5 years), and bedridden state (5 to 8 years). The median time from MSA onset to death is 6 to 10 years. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticipatory care</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical therapy is important for fall prevention, reduction in contractures, and maintenance of mobility. (See <a class="local">'Motor symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Occupational therapy may promote longer independence in performing activities of daily living.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Speech therapy referral early in the course of disease allows objective determination of the progression of dysphagia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Depression is a common problem in MSA. It should be identified early and treated appropriately. (See <a class="local">'Depression'</a> above and  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parkinsonism</strong> – Although a poor or unsustained response to levodopa therapy is generally observed in patients with MSA, some patients with clinically probable MSA do better with levodopa treatment than without it. The total daily dose of levodopa should be increased to 900 or 1000 mg daily before a trial of levodopa can be declared a failure. (See <a class="local">'Levodopa and dopaminergic therapy'</a> above.)</p><p></p><p class="bulletIndent2">Dopamine agonists (<a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a> and <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">ropinirole</a>) rarely lead to motor benefit and frequently exacerbate orthostatic hypotension, gastrointestinal symptoms, and sleep disorders that are prevalent in MSA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dystonia</strong> – Focal dystonia may be alleviated by botulinum toxin injection. (See <a class="local">'Motor symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Orthostatic hypotension</strong> – Treatment of orthostatic hypotension includes nonpharmacologic and pharmacologic measures  (<a class="graphic graphic_algorithm graphicRef130808" href="/z/d/graphic/130808.html" rel="external">algorithm 1</a>) as well as avoidance of aggravating medications when possible  (<a class="graphic graphic_table graphicRef130809" href="/z/d/graphic/130809.html" rel="external">table 3</a>). An approach to medication selection is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef130808" href="/z/d/graphic/130808.html" rel="external">algorithm 1</a>) and reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">"Treatment of orthostatic and postprandial hypotension"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laryngeal stridor</strong> – Patients with nocturnal stridor may benefit from nocturnal positive pressure ventilation; severe cases may necessitate tracheostomy. (See <a class="local">'Stridor'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sleep disturbances</strong> – Rapid eye movement (REM) sleep behavior disorder is common in patients with MSA and can lead to injury to the patient and bed partner. Treatment is reviewed in the algorithm and discussed separately  (<a class="graphic graphic_algorithm graphicRef134977" href="/z/d/graphic/134977.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef96339" href="/z/d/graphic/96339.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">"Rapid eye movement sleep behavior disorder", section on 'Management'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wenning GK, Ben Shlomo Y, Magalhães M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 ( Pt 4):835.</a></li><li><a class="nounderline abstract_t">Tada M, Onodera O, Tada M, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol 2007; 64:256.</a></li><li><a class="nounderline abstract_t">Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125:1070.</a></li><li><a class="nounderline abstract_t">Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008; 23:294.</a></li><li><a class="nounderline abstract_t">Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997; 48:384.</a></li><li><a class="nounderline abstract_t">Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry 2013; 84:136.</a></li><li><a class="nounderline abstract_t">Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12:264.</a></li><li><a class="nounderline abstract_t">Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 2015; 14:710.</a></li><li><a class="nounderline abstract_t">Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: A prospective cohort study. Neurology 2015; 85:1554.</a></li><li><a class="nounderline abstract_t">Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3:93.</a></li><li><a class="nounderline abstract_t">Petrovic IN, Ling H, Asi Y, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord 2012; 27:1186.</a></li><li><a class="nounderline abstract_t">Batla A, De Pablo-Fernandez E, Erro R, et al. Young-onset multiple system atrophy: Clinical and pathological features. Mov Disord 2018; 33:1099.</a></li><li><a class="nounderline abstract_t">O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131:1362.</a></li><li><a class="nounderline abstract_t">Coon EA, Sletten DM, Suarez MD, et al. Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 2015; 138:3623.</a></li><li><a class="nounderline abstract_t">Giannini G, Calandra-Buonaura G, Mastrolilli F, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology 2016; 87:1375.</a></li><li><a class="nounderline abstract_t">Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88:402.</a></li><li><a class="nounderline abstract_t">Calandra-Buonaura G, Guaraldi P, Sambati L, et al. Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue? Neurol Sci 2013; 34:1875.</a></li><li><a class="nounderline abstract_t">Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al. Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiol Dis 2020; 139:104813.</a></li><li><a class="nounderline abstract_t">Chelban V, Nikram E, Perez-Soriano A, et al. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 2022; 145:4398.</a></li><li><a class="nounderline abstract_t">Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8:1172.</a></li><li><a class="nounderline abstract_t">Meissner WG, Fernagut PO, Dehay B, et al. Multiple System Atrophy: Recent Developments and Future Perspectives. Mov Disord 2019; 34:1629.</a></li><li><a class="nounderline abstract_t">Burns MR, McFarland NR. Current Management and Emerging Therapies in Multiple System Atrophy. Neurotherapeutics 2020; 17:1582.</a></li><li><a class="nounderline abstract_t">Blaise AS, Cuvelier E, Carrière N, et al. Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy. Parkinsonism Relat Disord 2022; 100:41.</a></li><li><a class="nounderline abstract_t">Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol 2002; 9:195.</a></li><li><a class="nounderline abstract_t">Jain S, Dawson J, Quinn NP, Playford ED. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 2004; 19:1360.</a></li><li><a class="nounderline abstract_t">Thobois S, Broussolle E, Toureille L, Vial C. Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Disord 2001; 16:764.</a></li><li><a class="nounderline abstract_t">Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 2018; 33:372.</a></li><li><a class="nounderline abstract_t">Vichayanrat E, Hentzen C, Batla A, et al. Lower urinary tract dysfunction in Parkinsonian syndromes. Neurol Sci 2021; 42:4045.</a></li><li><a class="nounderline abstract_t">Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Relat Disord 2018; 57:22.</a></li><li><a class="nounderline abstract_t">Moussa M, Chakra MA, Dabboucy B, et al. The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. Scand J Urol 2022; 56:66.</a></li><li><a class="nounderline abstract_t">Cho SY, Jeong SJ, Lee S, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn 2021; 40:286.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat Disord 2015; 21:514.</a></li><li><a class="nounderline abstract_t">Claassen DO. Multiple System Atrophy. Continuum (Minneap Minn) 2022; 28:1350.</a></li><li><a class="nounderline abstract_t">Gray M, Skinner C, Kaler W. External Collection Devices as an Alternative to the Indwelling Urinary Catheter: Evidence-Based Review and Expert Clinical Panel Deliberations. J Wound Ostomy Continence Nurs 2016; 43:301.</a></li><li><a class="nounderline abstract_t">Ohshima Y, Nakayama H, Matsuyama N, et al. Natural course and potential prognostic factors for sleep-disordered breathing in multiple system atrophy. Sleep Med 2017; 34:13.</a></li><li><a class="nounderline abstract_t">Shimohata T, Aizawa N, Nakayama H, et al. Mechanisms and prevention of sudden death in multiple system atrophy. Parkinsonism Relat Disord 2016; 30:1.</a></li><li><a class="nounderline abstract_t">Rekik S, Martin F, Dodet P, et al. Stridor combined with other sleep breathing disorders in multiple system atrophy: a tailored treatment? Sleep Med 2018; 42:53.</a></li><li><a class="nounderline abstract_t">Iranzo A, Santamaria J, Tolosa E, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004; 63:930.</a></li><li><a class="nounderline abstract_t">Ghorayeb I, Yekhlef F, Bioulac B, Tison F. Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Med 2005; 6:359.</a></li><li><a class="nounderline abstract_t">Iranzo A, Santamaria J, Tolosa E. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet 2000; 356:1329.</a></li><li><a class="nounderline abstract_t">Silva C, Iranzo A, Maya G, et al. Stridor during sleep: description of 81 consecutive cases diagnosed in a tertiary sleep disorders center. Sleep 2021; 44.</a></li><li><a class="nounderline abstract_t">Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology 2019; 93:630.</a></li><li><a class="nounderline abstract_t">Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Disord 2000; 15:699.</a></li><li><a class="nounderline abstract_t">Giannini G, Provini F, Cani I, et al. Tracheostomy is associated with increased survival in Multiple System Atrophy patients with stridor. Eur J Neurol 2022; 29:2232.</a></li><li><a class="nounderline abstract_t">Jin K, Okabe S, Chida K, et al. Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology 2007; 68:1618.</a></li><li><a class="nounderline abstract_t">Lemos M, Wenning GK, Stefanova N. Current experimental disease-modifying therapeutics for multiple system atrophy. J Neural Transm (Vienna) 2021; 128:1529.</a></li><li><a class="nounderline abstract_t">Palma JA, Martinez J, Millar Vernetti P, et al. mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis. Mov Disord 2022; 37:778.</a></li><li class="breakAll">Study assessing safety and therapeutic activity of AFFITOPE® PD01A and PD03A in patients with early MSA (AFF009). https://clinicaltrials.gov/show/NCT02270489 (Accessed on May 09, 2017).</li><li><a class="nounderline abstract_t">Maab S, Levin J, Höglinger G. Current Treatment of Multiple System Atrophy. Curr Treat Options Neurol 2016; 18:51.</a></li><li><a class="nounderline abstract_t">Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72:32.</a></li><li><a class="nounderline abstract_t">Palma JA, Kaufmann H. Novel therapeutic approaches in multiple system atrophy. Clin Auton Res 2015; 25:37.</a></li><li><a class="nounderline abstract_t">Krismer F, Seppi K, Stefanova N, Wenning GK. Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. Mov Disord 2016; 31:235.</a></li><li><a class="nounderline abstract_t">Singer W, Dietz AB, Zeller AD, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 2019; 93:e77.</a></li><li class="breakAll">https://www.prnewswire.com/news-releases/biohavens-verdiperstat-receives-orphan-drug-designation-from-fda-for-multiple-system-atrophy-300797627.html (Accessed on February 19, 2019).</li><li><a class="nounderline abstract_t">Mészáros L, Hoffmann A, Wihan J, Winkler J. Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy. Int J Mol Sci 2020; 21.</a></li></ol></div><div id="topicVersionRevision">Topic 4891 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7922469" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296842" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960896" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18044727" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Survival in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040727" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Survival of patients with pathologically proven multiple system atrophy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23192520" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23391524" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The natural history of multiple system atrophy: a prospective European cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025783" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Natural history of multiple system atrophy in the USA: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432848" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Survival in synucleinopathies: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747001" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806758" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153390" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Young-onset multiple system atrophy: Clinical and pathological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385183" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369944" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features and autonomic testing predict survival in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566741" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early stridor onset and stridor treatment predict survival in 136 patients with MSA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28250027" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728718" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32087288" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35903017" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neurofilament light levels predict clinical progression and death in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19909915" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Multiple system atrophy: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31692132" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multiple System Atrophy: Recent Developments and Future Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32767032" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Current Management and Emerging Therapies in Multiple System Atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35716627" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11985626" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The symptomatic treatment of multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389983" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Occupational therapy in multiple system atrophy: a pilot randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481708" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508455" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34318363" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lower urinary tract dysfunction in Parkinsonian syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30037689" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34672847" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33389776" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25814050" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36222769" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Multiple System Atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974963" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : External Collection Devices as an Alternative to the Indwelling Urinary Catheter: Evidence-Based Review and Expert Clinical Panel Deliberations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28522081" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Natural course and potential prognostic factors for sleep-disordered breathing in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27103478" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mechanisms and prevention of sudden death in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29458746" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Stridor combined with other sleep breathing disorders in multiple system atrophy: a tailored treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365155" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15978519" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073029" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32954431" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Stridor during sleep: description of 81 consecutive cases diagnosed in a tertiary sleep disorders center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570638" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928581" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Stridor and death in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35384153" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Tracheostomy is associated with increased survival in Multiple System Atrophy patients with stridor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485650" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34398313" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Current experimental disease-modifying therapeutics for multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35040506" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35040506" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27787721" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Current Treatment of Multiple System Atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22829267" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A randomized trial of mesenchymal stem cells in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928797" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Novel therapeutic approaches in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26813934" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31152011" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31152011" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32316335" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
